Antipsychotics Associated with the Development of Type 2 Diabetes in Antipsychotic-Naïve Schizophrenia Patients

Cited by (205)

Items 201–205 of 205

1. Targeting Metabolic Abnormalities in Mental Health Prevention Strategies
   Simone Schimmenti, Francesca Maria Camilla Maselli, Sarah Tosato · 2022 · Springer eBooks
2. Heart rate variability and fasting plasma glucose as trait marker of psychosis: A comparative study between drug naive patients with psychosis and healthy volunteers
   Swayanka Samantray, Suvendu Narayan Mishra, Jitendriya Biswal, Debadatta Mohapatra · 2024 · Odisha Journal of Psychiatry
3. Clozapine induced globus pharyngeus: A case report
   Evaristus Chino Ezema, Bamidele O Johnson, Amir Meftah, Stanley Nkemjika, Bashir Aribisala, Tania Sultana, Esther U Ezenagu, Singh Satwant, Thant Htet, Jude Beauchamp et al. · 2024 · Psychiatry Research Case Reports
4. Additional file 1 of Orlistat for the treatment of antipsychotic-induced weight gain: an eight-week multicenter, randomized, placebo-controlled, double-blind trial
   Peng Xie, Tiannan Shao, Long, Yujun, Xie, Weiwei, Liu, Yangjun, Yang, Ye, Huang, Yuyan, Wu, Renrong, Deng, Qijian, Hui Tang · 2024 · Figshare
5. Short-, Medium-, and Long-Term Cardiometabolic Outcomes in First-Episode Psychosis: A Systematic Review and Meta-analysis
   Anna Zierotin, Jennifer Murphy, Anja Stano, Michael John Norton, David Cotter, Mary D Cannon, K. O’Connor, Brian N. O'Donoghue, Mary Clarke · 2026 · Schizophrenia Bulletin